Who
James L. Tyree
Director
Company insider
Files Form 4 as: Director, Genelux; Director, Assertio Holdings; Director, ChemoCentryx; Director, Assertio Therapeutics; Director, Innoviva; Executive Vice President, Abbott Laboratories.
In numbers
- Trades disclosed
- 299
- Buys
- 1
- Sells
- 28
- Bought
- $0
- Sold
- $19.5M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 14 Feb 2006
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —28,409 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,566 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,566 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —28,409 at $0.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,576 at $0.00 | filing |
| 27 Aug 2025filed 29 Aug 2025 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —22,283 at $0.00 | filing |
| 30 Dec 2024filed 30 Dec 2024 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $8,5123,460 at $2.46 | filing |
| 11 Sep 2024filed 12 Sep 2024 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $4,4981,730 at $2.60 | filing |
| 1 Aug 2024filed 31 Dec 2024 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,469 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,469 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —39,541 at $0.00 | filing |
| 29 May 2024filed 7 Jun 2024 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code P | —6,250 | filing |
| 29 May 2024filed 7 Jun 2024 | GNLX GeneluxBiotechnology | SEC FORM 4 Bought | —6,250 | filing |
| 14 Mar 2024filed 15 Mar 2024 | Assertio Holdings | SEC FORM 4 Sold | $11K10,251 at $1.12 | filing |
| 13 Dec 2023filed 14 Dec 2023 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $73K5,653 at $12.91 | filing |
| 13 Dec 2023filed 14 Dec 2023 | GNLX GeneluxBiotechnology | SEC FORM 4 Sold | $46K3,347 at $13.73 | filing |
| 11 Sep 2023filed 13 Sep 2023 | GNLX Geneluxoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,397 at $0.00 | filing |
| 11 Sep 2023filed 13 Sep 2023 | GNLX GeneluxBiotechnology | SEC FORM 4 Code A | —3,460 at $0.00 | filing |
| 10 May 2023filed 12 May 2023 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —3,821 at $0.00 | filing |
| 10 May 2023filed 12 May 2023 | Assertio Holdings | SEC FORM 4 Code A | —31,194 at $0.00 | filing |
News
Abbott Laboratories announces a baby formula spinoff companyABT · marketplace.org · 21 Oct 2026Abbott anticipates nutrition separation by end of next year and forecasts Q4 adjusted EPS of $1.62-$1.67 (NYSE:ABT)ABT · seekingalpha.com · 21 Oct 2026Abbott Laboratories plans to spin off nutrition businessABT · chicagotribune.com · 21 Oct 2026Head-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)GNLX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name James L. Tyree; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.